Eribulin
- Generic Name
- Eribulin
- Brand Names
- Halaven, Eribulin Baxter, Mevlyq
- Drug Type
- Small Molecule
- Chemical Formula
- C40H59NO11
- CAS Number
- 253128-41-5
- Unique Ingredient Identifier
- LR24G6354G
- Background
Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .
- Indication
For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.
- Associated Conditions
- Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma
First Line Metastatic Breast Cancer Treatment (ESMERALDA)
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 61
- Registration Number
- NCT01941407
- Locations
- 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷Clinique Tivoli, Bordeaux, France
🇫🇷Centre Hospitalier d'Auxerre, Auxerre, France
Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer
- Conditions
- Metastatic Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT01912963
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
- Conditions
- Recurrent Breast CarcinomaStage IV Breast Cancer
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 86
- Registration Number
- NCT01908101
- Locations
- 🇺🇸
Skagit Valley Hospital, Mount Vernon, Washington, United States
🇺🇸Olympic Medical Center, Port Angeles, Washington, United States
🇺🇸Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States
Eribulin in HER2 Negative Metastatic BrCa
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 83
- Registration Number
- NCT01827787
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸DF/BWCC at Milford Regional Cancer Center, Milford, Massachusetts, United States
🇺🇸South Shore Hospital, Weymouth, Massachusetts, United States
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2022-10-31
- Target Recruit Count
- 19
- Registration Number
- NCT01795586
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
- Conditions
- HER2-negative Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 50
- Registration Number
- NCT01705691
- Locations
- 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇨🇦Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada
🇨🇦Montreal General Hospital, Montreal, Quebec, Canada
Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer
- Conditions
- Recurrent Cervical CancerStage IIIA Cervical CancerStage IIIB Cervical CancerStage IVA Cervical CancerStage IVB Cervical Cancer
- Interventions
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 32
- Registration Number
- NCT01676818
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer
- First Posted Date
- 2012-08-20
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- SOLTI Breast Cancer Research Group
- Target Recruit Count
- 163
- Registration Number
- NCT01669252
- Locations
- 🇵🇹
Hospital da Luz, Lisboa, Portugal
🇪🇸Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
- Conditions
- Stage IVC Salivary Gland CancerStage IVA Salivary Gland CancerStage IVB Salivary Gland CancerRecurrent Salivary Gland Cancer
- Interventions
- First Posted Date
- 2012-06-07
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 29
- Registration Number
- NCT01613768
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- Hope Rugo, MD
- Target Recruit Count
- 67
- Registration Number
- NCT01596751
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Duke University Cancer Center, Durham, North Carolina, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.